Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

R. T. Prall, Keith Lindor, R. H. Wiesner, N. F. LaRusso

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterized by fibrosing inflammation of the intrahepatic and extrahepatic bile ducts, leading ultimately to cirrhosis and death caused by complications from liver failure if liver transplantation is not peformed. Despite a better understanding of the natural history of the disease, no significant breakthroughs have been made into its pathogenesis. Over the past decade and a half, many clinical trials of medical therapy have been conducted; however, none have demonstrated real efficacy. This reflects our lack of understanding into the basic mechanisms of disease pathogenesis in PSC. Progress has been made in the area of orthotopic liver transplantation for PSC, and to some extent in the diagnosis and management of complications, the most grave of which is the development of cholangiocarcinoma. This review highlights the progress that has been made, describes our current deficiencies, and discusses likely developments in the future. The authors also discuss management controversies and provide current practice guidelines where applicable.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalCurrent Gastroenterology Reports
Volume2
Issue number2
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Liver Transplantation
Intrahepatic Bile Ducts
Extrahepatic Bile Ducts
Cholangiocarcinoma
Liver Failure
Practice Guidelines
Liver Diseases
Fibrosis
Therapeutics
Clinical Trials
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current therapies and clinical controversies in the management of primary sclerosing cholangitis. / Prall, R. T.; Lindor, Keith; Wiesner, R. H.; LaRusso, N. F.

In: Current Gastroenterology Reports, Vol. 2, No. 2, 04.2000, p. 99-103.

Research output: Contribution to journalArticle

@article{ab07fc554394496dae4bc0a0ed7f5a6e,
title = "Current therapies and clinical controversies in the management of primary sclerosing cholangitis.",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterized by fibrosing inflammation of the intrahepatic and extrahepatic bile ducts, leading ultimately to cirrhosis and death caused by complications from liver failure if liver transplantation is not peformed. Despite a better understanding of the natural history of the disease, no significant breakthroughs have been made into its pathogenesis. Over the past decade and a half, many clinical trials of medical therapy have been conducted; however, none have demonstrated real efficacy. This reflects our lack of understanding into the basic mechanisms of disease pathogenesis in PSC. Progress has been made in the area of orthotopic liver transplantation for PSC, and to some extent in the diagnosis and management of complications, the most grave of which is the development of cholangiocarcinoma. This review highlights the progress that has been made, describes our current deficiencies, and discusses likely developments in the future. The authors also discuss management controversies and provide current practice guidelines where applicable.",
author = "Prall, {R. T.} and Keith Lindor and Wiesner, {R. H.} and LaRusso, {N. F.}",
year = "2000",
month = "4",
language = "English (US)",
volume = "2",
pages = "99--103",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

AU - Prall, R. T.

AU - Lindor, Keith

AU - Wiesner, R. H.

AU - LaRusso, N. F.

PY - 2000/4

Y1 - 2000/4

N2 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterized by fibrosing inflammation of the intrahepatic and extrahepatic bile ducts, leading ultimately to cirrhosis and death caused by complications from liver failure if liver transplantation is not peformed. Despite a better understanding of the natural history of the disease, no significant breakthroughs have been made into its pathogenesis. Over the past decade and a half, many clinical trials of medical therapy have been conducted; however, none have demonstrated real efficacy. This reflects our lack of understanding into the basic mechanisms of disease pathogenesis in PSC. Progress has been made in the area of orthotopic liver transplantation for PSC, and to some extent in the diagnosis and management of complications, the most grave of which is the development of cholangiocarcinoma. This review highlights the progress that has been made, describes our current deficiencies, and discusses likely developments in the future. The authors also discuss management controversies and provide current practice guidelines where applicable.

AB - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterized by fibrosing inflammation of the intrahepatic and extrahepatic bile ducts, leading ultimately to cirrhosis and death caused by complications from liver failure if liver transplantation is not peformed. Despite a better understanding of the natural history of the disease, no significant breakthroughs have been made into its pathogenesis. Over the past decade and a half, many clinical trials of medical therapy have been conducted; however, none have demonstrated real efficacy. This reflects our lack of understanding into the basic mechanisms of disease pathogenesis in PSC. Progress has been made in the area of orthotopic liver transplantation for PSC, and to some extent in the diagnosis and management of complications, the most grave of which is the development of cholangiocarcinoma. This review highlights the progress that has been made, describes our current deficiencies, and discusses likely developments in the future. The authors also discuss management controversies and provide current practice guidelines where applicable.

UR - http://www.scopus.com/inward/record.url?scp=0034169787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034169787&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 99

EP - 103

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 2

ER -